PSMA2 overexpression is observed in ovarian cancer [33], and chemokine ligand 9 (CXCL9) is a vascular inhibitor that could inhibit ovarian cancer through lymphocyte invasion [34, 35]. Here, CXCL9 is linked to ovarian carcinoma.